False positive serum vascular endothelial growth factor-D in a patient with Birt-Hogg-Dubé syndrome Authors: Prachi Saluja, Sarah K. Shore, Charles M. Lombard, Stephen J. Ruoss, Nishant Gupta Published: 2026 ABSTRACT Diffuse cystic lung diseases (DCLDs) are a heterogeneous group of disorders requiring careful evaluation due to distinct management and prognostic implications. A 32-year-old woman presented with dyspnea and chest pressure following a coughing episode and was found to have a right-sided pneumothorax. CT chest showed bilateral, small, round-elliptiform, basal-predominant cysts. Workup, including autoimmune serologies and abdominal imaging, was unrevealing. Serum vascular endothelial growth factor (VEGF)-D was elevated at 839pg/ml, supporting a clinical diagnosis of lymphangioleiomyomatosis (LAM). However, critical re-evaluation of cyst morphology was more suggestive of Birt-Hogg-Dubé syndrome (BHD). Genetic testing revealed a pathogenic folluculin gene mutation, thus confirming the diagnosis of BHD. Surgical lung biopsy, obtained afterwards at the time of elective pleurodesis, did not reveal features of LAM. This case represents a rare instance of falsely elevated VEGF-D in patient with non-LAM DCLD and highlights the importance of critical review of chest radiology in the diagnostic evaluation of patients with cystic lung disease. Introduction Diffuse cystic lung diseases (DCLDs) encompass a group of pathophysiologically distinct disorders characterized by well-defined, air-filled, hyperlucent areas within the pulmonary parenchyma that interface with normal lung tissue [1]. High-resolution chest tomography (HRCT) plays a key role in the identification of cysts and revealing cyst distribution and morphological patterns that aid in definitive diagnosis. Accurate identification is crucial, as management strategies and prognosis differ substantially among the individual DCLDs. Case presentation A 32-year-old non-smoking woman presented with acute onset dyspnea and chest pressure following a coughing spell. Her past medical history and physical exam were otherwise unremarkable. Her only outpatient medication was a high-dose estrogen-containing oral contraceptive, which had been discontinued two months prior to presentation. Chest radiograph revealed a right-sided spontaneous pneumothorax, which was managed with a small-bore chest tube. Due to a prolonged air leak, a CT chest was obtained, revealing multiple, bilateral, small, round-elliptiform cysts with slight basal predominance (Fig. 1). She did not have any other features suggestive of underlying autoimmune disorders or Tuberous Sclerosis Complex (TSC) and her family history was unremarkable. No renal tumors or lymphadenopathy were noted on abdominal imaging. Laboratory assessments, including connective tissue disease serologies, alpha-1 antitrypsin levels, and immunoglobulin levels were within normal limits, except for elevated serum vascular endothelial growth factor-D (VEGF-D) level of 839pg/ml.Fig. 1Chest radiology and histopathology in our case: Figures A, B and C show small elliptiform cysts (arrows) that are basilar and peripheral predominant, in axial, coronal, and sagittal sections of chest CT, respectively. Figures D, E and F are wedge biopsies of lung stained with hematoxylin and eosin and seen under 1x (Figure D) and 10x (Figures E and F) original magnification. No inflammation or fibrosis is present and there is no proliferation of LAM cells. Figure D: The lung shows areas of subpleural emphysematous change (arrow). There is an adjacent area of pulmonary bleb/cyst formation (∗). Figure E: The area of pulmonary bleb/cyst formation from Figure D is present adjacent to emphysematous pulmonary tissues (arrow). There is no distinct cyst lining. Figure F: Additional areas of subpleural bleb/cyst formation are present (arrows). Flattened alveolar epithelium lines the subpleural aspects of the cystic areas (arrows). The opposite border of these cystic areas abuts on emphysematous pulmonary tissues. Chest radiology and histopathology in our case: Figures A, B and C show small elliptiform cysts (arrows) that are basilar and peripheral predominant, in axial, coronal, and sagittal sections of chest CT, respectively. Figures D, E and F are wedge biopsies of lung stained with hematoxylin and eosin and seen under 1x (Figure D) and 10x (Figures E and F) original magnification. No inflammation or fibrosis is present and there is no proliferation of LAM cells. Figure D: The lung shows areas of subpleural emphysematous change (arrow). There is an adjacent area of pulmonary bleb/cyst formation (∗). Figure E: The area of pulmonary bleb/cyst formation from Figure D is present adjacent to emphysematous pulmonary tissues (arrow). There is no distinct cyst lining. Figure F: Additional areas of subpleural bleb/cyst formation are present (arrows). Flattened alveolar epithelium lines the subpleural aspects of the cystic areas (arrows). The opposite border of these cystic areas abuts on emphysematous pulmonary tissues. Given the clinical presentation of a premenopausal woman with spontaneous pneumothorax, bilateral cystic lung disease on chest CT, and elevated serum VEGF-D >800pg/ml, a clinical diagnosis of lymphangioleiomyomatosis (LAM) was established in accordance with the LAM Clinical Practice Guidelines [2]. However, a critical re-evaluation of her chest CT findings suggested that the cyst features were more consistent with Birt-Hogg-Dubé (BHD) syndrome rather than LAM. This prompted genetic testing that revealed a pathogenic folliculin (FLCN) gene mutation (pF157del), thus confirming the diagnosis of BHD. To reduce the risk of future pneumothoraces and to exclude the possibility of two simultaneous disease processes, she underwent video-assisted thoracoscopic surgery (VATS) guided pleurodesis and lung biopsy, which did not reveal features of LAM and supported the diagnosis of BHD (Fig. 1). Discussion LAM is a rare, female-predominant, low-grade neoplasm caused by mutations in the TSC genes that causes progressive cystic lung destruction driven by hyperactivated mechanistic target of rapamycin (mTOR) signaling [3]. Serum VEGF-D ≥800pg/ml has been reported to be 100% specific in being able to distinguish LAM from other DCLDs and is recommended as a non-invasive confirmatory test prior to pursuing invasive options such as lung biopsy [3,4]. In the United States (US), serum VEGF-D quantification in a CAP/CLIA-accredited manner is performed exclusively at Cincinnati Children's Hospital Medical Center. To our knowledge, this is the first reported instance of false positive serum VEGF-D >800pg/ml in a woman with non-LAM DCLD in the US. A similar case of false positive VEGF-D greater 800pg/ml (860pg/ml) in patient with BHD has been previously reported in France [5]. BHD is an autosomal dominant disorder driven by mutations in the FLCN gene, a tumor suppressor gene, that predisposes patients to the development of renal tumors, hair follicle tumors and pulmonary cysts [6]. Although the mechanism of pulmonary cyst formation in BHD is not completely understood, a potential role of mTOR signaling in BHD pathogenesis has been postulated [7]. The phenotypic similarities between BHD and TSC – skin lesions, renal tumors, pulmonary cysts, further suggest the potential for mechanistic overlap between these two disorders. VEGF-D production in LAM appears to be driven by activated mTOR signaling – serum VEGF-D levels decrease in response to treatment with mTOR inhibitors and rise again after the therapy is withheld [8]. Thus, it is possible that elevated VEGF-D in this case might be driven by activated mTOR signaling. Our case and its notable finding of elevated serum VEGF-D highlight the need for further investigation of the role of mTOR signaling in the pathogenesis of BHD. Although LAM and BHD share the radiologic phenotype of diffuse pulmonary cysts, there are some key differences between the two diseases (Table 1). Critical review of chest CT findings focusing on cyst morphology, profusion, and distribution can provide helpful clues to reliably distinguish BHD and LAM [9]. Ascertaining the correct diagnosis between BHD and LAM has significant prognostic and management implications. LAM is a progressive disease that can benefit from treatment with mTOR inhibitors. In contrast, lung disease in BHD is typically mild, doesn't seem to progress appreciably over time, and does not have known pharmacological treatment [6]. Specifically, for our case, she was contemplating pregnancy, which is known to be associated with high risk of accelerated disease progression in women with LAM [10] while no such risk is known in BHD.Table 1Key differences between lymphangioleiomyomatosis and Birt-Hogg-Dubé syndrome.Table 1VariablesLymphangioleiomyomatosisBirt-Hogg-Dubé syndromeDemographicsAlmost exclusively seen in womenNo known gender predilectionCyst features on chest CTDiffuse, no lobar predilection, round, uniform in size and shapeBasilar and peripheral predominant, elliptical or lentiform, can be variable in shape and size, often abutting the pleura or pulmonary vesselsAdditional clues in history or examCyclical symptom variability with menstrual cycle.Positive family history for renal cancer or pneumothoraces.Skin exam showing fibrofolliculomas or trichodiscomas.Worsening symptoms with exogenous estrogen use or during pregnancy.Dermatological findings in patients with TSC-LAM such as periungal fibromas, facial angiofibromas, hypomelanotic macules and Shagreen patch.Abdominopelvic imagingRenal angiomyolipomas, lymphadenopathy or lymphangioleiomyomasRenal tumors; can be bilateral and/or multifocalLong-term pulmonary outcomeProgressive respiratory failure unless treatedGenerally, doesn't progressMain management considerationsPharmacologic therapy with mTOR inhibitorsSurveillance for renal tumors Family member screeningAbbreviations: mTOR = mechanistic target of rapamycin; TSC = Tuberous Sclerosis Complex. Table 1Key differences between lymphangioleiomyomatosis and Birt-Hogg-Dubé syndrome.Table 1VariablesLymphangioleiomyomatosisBirt-Hogg-Dubé syndromeDemographicsAlmost exclusively seen in womenNo known gender predilectionCyst features on chest CTDiffuse, no lobar predilection, round, uniform in size and shapeBasilar and peripheral predominant, elliptical or lentiform, can be variable in shape and size, often abutting the pleura or pulmonary vesselsAdditional clues in history or examCyclical symptom variability with menstrual cycle.Positive family history for renal cancer or pneumothoraces.Skin exam showing fibrofolliculomas or trichodiscomas.Worsening symptoms with exogenous estrogen use or during pregnancy.Dermatological findings in patients with TSC-LAM such as periungal fibromas, facial angiofibromas, hypomelanotic macules and Shagreen patch.Abdominopelvic imagingRenal angiomyolipomas, lymphadenopathy or lymphangioleiomyomasRenal tumors; can be bilateral and/or multifocalLong-term pulmonary outcomeProgressive respiratory failure unless treatedGenerally, doesn't progressMain management considerationsPharmacologic therapy with mTOR inhibitorsSurveillance for renal tumors Family member screeningAbbreviations: mTOR = mechanistic target of rapamycin; TSC = Tuberous Sclerosis Complex. Key differences between lymphangioleiomyomatosis and Birt-Hogg-Dubé syndrome. Abbreviations: mTOR = mechanistic target of rapamycin; TSC = Tuberous Sclerosis Complex. Conclusion In our case, establishing the correct diagnosis of BHD led to a more reassuring prognostication for the patient, enabled her to make the decision to pursue pregnancy, and obviated the need for long-term treatment with sirolimus. This case cautions clinicians on relying solely on a single diagnostic test and underscores the importance of critical review of the radiological features when evaluating patients with DCLD. Consent Obtained. Ethics declaration Not Applicable. CRediT authorship contribution statement Prachi Saluja: Data curation, Formal analysis, Writing – original draft, Writing – review & editing. Sarah K. Shore: Data curation. Charles M. Lombard: Data curation, Writing – review & editing. Stephen J. Ruoss: Data curation, Supervision, Writing – review & editing. Nishant Gupta: Conceptualization, Data curation, Supervision, Writing – review & editing. Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.